Clinical Trials · NCT02060266

Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

Name: Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Semaglutide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Novo Nordisk A/S
Enrollment: 7
Start date: Feb 2014
Locations: 1 site, Netherlands
Primary endpoint: Concentration of the major metabolites of [3H]-semaglutide in plasma, urine, and faeces

View Semaglutide compound reference